Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher

The Details:

Clearmind said the allowed claims are directed to use a primary amine aminoindan compound to regulate binge behavior, including primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan (MEAI), the company’s innovative psychedelic molecule. 

MEAI is a psychoactive molecule that reduces the desire to consume alcoholic beverages and provides a slight euphoric, alcohol-like experience. Clearmind’s MEAI-based flagship treatment focuses on Alcohol Use Disorder and weight loss. MEAI may also be used to treat binge drinking, according to Clearmind. 

The company has 28 granted patents across 18 patent families, with patents granted in major jurisdictions such as the U.S., Europe, China, India and Hong Kong.

Clearmind shares are moving on heavy trading volume following the company's announcement with more than 70.7 million shares already traded in Friday's session. According to data from Benzinga Pro, the stock’s 100-day average volume is less than 1.3 million shares.

Related News: Elon Musk’s Tesla Pay Package Saga Continues: Latest Developments

How To Buy CMND Stock:

By now you're likely curious about how to participate in the market for Clearmind Medicine – be it to purchase shares, or even attempt to bet against the company.

In the the case of Clearmind Medicine, which is trading at $1.71 as of publishing time, $100 would buy you 58.48 shares of stock.

CMND Price Action: According to Benzinga Pro, Clearmind Medicine shares are up 29.1% at $1.73 at the time of publication Friday.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.